- Home
- CNSP vs QNRX Comparison
CNSP vs QNRX Comparison
Compare CNSP & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNSP
- QNRX
- Stock Information
- Founded
- CNSP 2017
- QNRX 2018
- Country
- CNSP United States
- QNRX United States
- Employees
- CNSP N/A
- QNRX N/A
- Industry
- CNSP Biotechnology: Pharmaceutical Preparations
- QNRX Medical/Dental Instruments
- Sector
- CNSP Health Care
- QNRX Health Care
- Exchange
- CNSP Nasdaq
- QNRX Nasdaq
- Market Cap
- CNSP 4.0M
- QNRX 4.3M
- IPO Year
- CNSP 2019
- QNRX N/A
- Fundamental
- Price
- CNSP $6.19
- QNRX $7.15
- Analyst Decision
- CNSP Hold
- QNRX
- Analyst Count
- CNSP 1
- QNRX 0
- Target Price
- CNSP N/A
- QNRX N/A
- AVG Volume (30 Days)
- CNSP 41.8K
- QNRX 4.3K
- Earning Date
- CNSP 08-14-2025
- QNRX 08-07-2025
- Dividend Yield
- CNSP N/A
- QNRX N/A
- EPS Growth
- CNSP N/A
- QNRX N/A
- EPS
- CNSP N/A
- QNRX N/A
- Revenue
- CNSP N/A
- QNRX N/A
- Revenue This Year
- CNSP N/A
- QNRX N/A
- Revenue Next Year
- CNSP N/A
- QNRX N/A
- P/E Ratio
- CNSP N/A
- QNRX N/A
- Revenue Growth
- CNSP N/A
- QNRX N/A
- 52 Week Low
- CNSP $4.93
- QNRX $5.01
- 52 Week High
- CNSP $221.94
- QNRX $54.95
- Technical
- Relative Strength Index (RSI)
- CNSP 35.47
- QNRX 41.22
- Support Level
- CNSP $4.93
- QNRX $7.05
- Resistance Level
- CNSP $7.75
- QNRX $7.80
- Average True Range (ATR)
- CNSP 0.79
- QNRX 0.37
- MACD
- CNSP -0.08
- QNRX 0.04
- Stochastic Oscillator
- CNSP 37.06
- QNRX 38.18
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.